retatrutide sleep apnea Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide clinical study Eli Lilly

Finally, although most of the evidence of a potential benefit of GLP-1 RAs in HF originates from CVOTs in type 2 diabetes, it may likely be in the weight management setting that the drug class could be of the highest clinical value, particularly in people with HFpEF

JAMA: The Journal Of The American Medical Association 2001, 286: 2849-2856

Zittoun J, Farcet JP, Marquet J, Sultan C, Zittoun R

Second, as the main analysis, we used a per-protocol approach to estimate the increased risk of SIS in GLP-1RA vs SGLT-2i users

When researchers used erythromycin (a prokinetic) to override the effects on stomach emptying, GLP-1's ability to lower glucose dropped [3]